Last reviewed · How we verify
Long GnRH agonist — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Long GnRH agonist (Long GnRH agonist) — Merck KGaA, Darmstadt, Germany.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Long GnRH agonist TARGET | Long GnRH agonist | Merck KGaA, Darmstadt, Germany | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Long GnRH agonist CI watch — RSS
- Long GnRH agonist CI watch — Atom
- Long GnRH agonist CI watch — JSON
- Long GnRH agonist alone — RSS
Cite this brief
Drug Landscape (2026). Long GnRH agonist — Competitive Intelligence Brief. https://druglandscape.com/ci/long-gnrh-agonist. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing